You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (8)

Journals (0)

1-8 of 8 results for factor IXa inhibitors

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism

Retricted access

Research article

First published 2016-8

Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism

Sandeep Devabhakthuni, Connie H. Yoon, Kathleen J. Pincus

Journal of Pharmacy Practice

Select article: The role of emicizumab,a bispecific factor IXa- and factor X-directed antibody,for the prevention of bleeding episodes in patients with hemophilia A

Free access

Review article

First published 2018-10

The role of emicizumab,a bispecific factor IXa- and factor X-directed antibody,for the prevention of bleeding episodes in patients with hemophilia A

Tristan Knight, Michael U. Callaghan

Therapeutic Advances in Hematology

Select article: State-of-the-Art Review : Role of Antithrombin and Tissue Factor Pathway Inhibitor in the Control of Thrombosis and Mediation of Heparin Action

Retricted access

Review article

First published 1996-01

State-of-the-Art Review : Role of Antithrombin and Tissue Factor Pathway Inhibitor in the Control of Thrombosis and Mediation of Heparin Action

Nina Iverson, Ulrich Abildgaard

Clinical and Applied Thrombosis/Hemostasis

Select article: Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

Retricted access

Research article

First published 2019-9

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

Dawid L Staudacher, Vera Putz, Lukas Heger [...]

European Heart Journal: Acute Cardiovascular Care

Select article: Antithrombin Concentrates: Clinical Indications

Retricted access

Other

First published 1998-01

Antithrombin Concentrates: Clinical Indications

Helmut Vinazzer

Clinical and Applied Thrombosis/Hemostasis

Select article: Protein S and Thrombotic Disease

Retricted access

Research article

First published 1992-7

Protein S and Thrombotic Disease

Frederick J. Walker

Experimental Biology and Medicine

Select article: Antithrombin Concentrates in Heparin-Resistant Cardiopulmonary Bypass Patients

Retricted access

Research article

First published 1996-04

Antithrombin Concentrates in Heparin-Resistant Cardiopulmonary Bypass Patients

Mehraboon S. Irani

Clinical and Applied Thrombosis/Hemostasis

Select article: {BLR 2470}Acorda - Activated Cell Therapy - Alferon - American Red Cross - Amgen - Anti-Infective Agents - Bioimmune Systems - Cancer - Chiral Drugs - Chirex - Cholestech - Colon Cancer - Columbia University - Cyberchemics - Cyclins - Duke University - Elan Corp. - Entremed - Factor Ixa Inhibitor - Fampridine - First Medical - Fish - Gene Therapy - Geron - Harvard Medical School - Health Management Systems - Hepatitis C - Icos - Interferon Sciences - Interneuron - Kinetic Resolution Technology - Leptin - Mabs - Memorial Sloan- Kettering - Pharmacia & Upjohn - Platelet-Activating Factor - Proscript - Purdue Pharma - Sequana Therapeutics - Spinal Cord Injury - Structural Bioinformatics - Suntory - Telomerase - Terrapin - Thrombolysis - University Of Arizona - University Of Chicago - Varian - Vimrx - Vysis - Wal-Mart - Walter Reed Army Institute

Retricted access

News

First published 1997-07

{BLR 2470}Acorda - Activated Cell Therapy - Alferon - American Red Cross - Amgen - Anti-Infective Agents - Bioimmune Systems - Cancer - Chiral Drugs - Chirex - Cholestech - Colon Cancer - Columbia University - Cyberchemics - Cyclins - Duke University - Elan Corp. - Entremed - Factor Ixa Inhibitor - Fampridine - First Medical - Fish - Gene Therapy - Geron - Harvard Medical School - Health Management Systems - Hepatitis C - Icos - Interferon Sciences - Interneuron - Kinetic Resolution Technology - Leptin - Mabs - Memorial Sloan- Kettering - Pharmacia & Upjohn - Platelet-Activating Factor - Proscript - Purdue Pharma - Sequana Therapeutics - Spinal Cord Injury - Structural Bioinformatics - Suntory - Telomerase - Terrapin - Thrombolysis - University Of Arizona - University Of Chicago - Varian - Vimrx - Vysis - Wal-Mart - Walter Reed Army Institute

Biotechnology Law Report

1
10 / page

Article type

Publication date

Subjects

Access